

References

- **Aarskog, D.; Aksnes, L.;Markestad, T. and et al (2000):** Effect parathyroid hormone on cAMP and 1,25dihydroxy vitamin D formation and renal handling of phosphate in vitamin D-dependant rickets . Pediatrics; 71:59.
- **Adams, J.S. (2000):** Metabolism and biological function of vitamin D: Metabolic bone Disease , S.M.Krane (ed) San Diego , Academic Press, 123-163.
- **Altet Gómez MN, Alcáide Megías J and Boque Genovard MA(1984).** Toxicity in the current treatment of pulmonary tuberculosis in children [Article in Spanish]. An Esp Pediatr ; 20:18-27.
- **Alvarez, S.Z. and Carpio, R(1983).** Hepatobiliary tuberculosis. Dig. Dis. Sci.; 28,193.
- **American Academy of pediatrics (2006)(a) :** Diagnosis And Management of pulmonary tuberculosis. Pediatrics, 19, 383-8.
- **American Academy of Pediatrics (2006)(b).** Committee on Infectious Diseases. Red book: 2006. Report of the Committee on Infectious Diseases. American Academy of Pediatrics; .
- **American Academy of Pediatrics(2000)(a).** Measles. In: Picketing LK, editor. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village (IL): American Academy of Pediatrics; . p. 394.
- **American Academy of Pediatrics(2000)(b).** Tuberculosis. In: Picketing LK, editor. Red Book: Report of the Committee on

- Infectious Diseases. 25th ed. Elk Grove Village (IL):American Academy of Pediatrics; . p. 596.
- **American Academy of Pediatrics(2009).** Tuberculosis. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering, LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL . p. 680.
 - **American Academy of Pediatrics(2012).**diagnosis tuberculosis in children. Source Caring for Your Baby and Young Child: Birth to Age 5.
 - **American Lung Association (2007):** Pediatric Tuberculosis Fact Sheet. <http://www.lungusa.org>
 - **American Thoracic Society and Centers for Disease Control and Prevention(2000)(a).** Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med ;161:1376-1395.
 - **American Thoracic Society Update(2001).** Fatal and severe liver injuries associated with Rifampicin and Pyrazinamide for latent tuberculosis infections, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. Am J Respir Crit Care Med ;164:1319- 1320.
 - **American Thoracic Society(1992).** Control of tuberculosis .
 - **American Thoracic Society(2000)(b).**Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR Morb Mortal Wkly Rep.* ;49(RR-6):1-51.
 - **American Thoracic Society/Centers for Disease Control and Prevention(2000)(c).** Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med ; 161: S221–S247

- **Anane T, Cernay J, Bensenouci A, Zaouche A, Boukhelal H, Laalaoui SE and et al.(1992).** An Algerian experiment: short chemotherapy for tuberculosis. *Child Trop* ; 196-197: 78-82.
- **Andersen P(2007).** Vaccine strategies against latent tuberculosis infection.*Trends Microbiol* ; **15**: 7–13.
- **Anderson BL, Litwin CM and Welch RJ(2008).** Assessment of three commercially available assays for detection of antibodies to mycobacteria tuberculosis. *Clin Vaccine Immunol* November 2008 vol. 15 no. 11 1644-1649.
- **Arif MA, Qureshi AF and Rahimtoola RJ(1977).** Aspects of pediatric Liver disease in Karachi. *J Pak Med Assoc* ; 27: 296-9.
- **Aronson NE, Santosham M, Comstock GW and et al.(2004).** Long-term efficacy of BCG vaccine in American Indians and Alaska Natives:a 60-year follow-up study. *JAMA* ; 291: 2086–91.
- **Askgaard DS, Wilcke T and Dossing M(1995).** Hepatotoxicity caused by the combined treatment action of isoniazid and rifampicin. *Thorax* ; 50: 213–214.
- **ATS/CDCP (American Thoracic Society : Centers for Diseases Control and Prevention/ Infection Diseases Society of America) (2003):** Treatment of tuberculosis. *Am J Respir Crit Care Med*; 167: 603- 662.
- **Baigent MJ (2003):** Vitamins. In,kalant H and Roschau WHE (eds), *Principles of medical pharmacology*, 6th ed., ch.67, New York. Oxford University Press:836-840.
- **Barnes PF, Bloch AB, Davidson PT and et al.(1991).** Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med.* ;100:191-200.

-
- **Bastani B, Shariatzadeh MR and Dehdashti F(1985).** Tuberculous peritonitis: report of 30 cases and review of the literature. *Q J Med.* ;56:549-557.
 - **Behera SK, Das PK, Samal GC, Ahmed B and Swain U(1977).** Histopathological study of the liver in childhood tuberculosis. *Indian J Pediatr*; 44: 364-8.
 - **Behr MA, Wilson MA, Gill WP and et al.(1999).** Comparative genomics of BCG vaccines by whole-genome DNA microarray. *Science* ; **284**: 1520–23.
 - **Bellamy R(2005).** Genetic susceptibility to tuberculosis. *Clin Chest Med* 2005; **26**: 233–46
 - **Benichou C(1990).** Criteria for drug-induced liver disorder: report of an international consensus meeting. *J Hepatol* ; 11: 272–276.
 - **Bhagavan NV (2002):** Mineral metabolism: Medical Biochemistry, fourth edition. Harcourt/ Academic press, 874-880.
 - **Binkin NJ, Zuber PLF, Wells CD and et al.(1997).** Overseas screening for tuberculosis in immigrants and refugees to the United States: current status. *Clin Infect Dis.* ; 23:1226-1232.
 - **Bischoff-Ferrari, HA, Giovannucci, E, Willett, WC and et al.(2006).** Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* ; 84:18.
 - **Bischoff-Ferrari, HA, Willett, WC, Wong, JB and et al.(2005).** Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* ; 293:2257.
 - **Blangy, S., Cornud, F. and Sibert, A(1988).** Hepatic tuberculosis presenting as tumoral disease. *Gastrointest Radiol.*; 13,52.
 - **Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN and et al.(2003).**American Thoracic Society,
-

- Centers for Disease Control and Prevention and the Infectious Diseases Society: treatment of tuberculosis. *Am J Respir Crit Care Med* ; 167: 603–662.
- **Bonington A, Strang JI, Klapper PE and et al.(1998).** Use of Roche AMPLICOR Mycobacterium PCR in early diagnosis of tuberculous meningitis. *J Clin Microbiol.* ;36:1251-1254.
 - **Bothamley GH(2002).** Treatment, tuberculosis, and human leukocyte antigen. *Am J Respir Crit Care Med* ;166:907–908.
 - **Bouros D, Zeros G, Panaretos C, Vassilatos C and Siafakas N(1991).** Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). *Chest* ;99:416-9
 - **Brauner, M., Buffard, M.D., Jeantils, V. and et al.(1989).** Sonography and computed tomography of macroscopic tuberculosis of the liver. *J. Clin. Ultrasound*; 17,563.
 - **Breen RA, Smith CJ, Bettinson H and et al.(2004).** Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. *Thorax* ; 59: 704–707.
 - **Brimlecomb, F. & Barltrop, D. (1978):** Children in health & disease ,Baillier, Tindall, London P57-82.
 - **Bringham FR (2002):** Regulation of calcium and phosphate homeostasis. In: endocrinology, 4 ed, Degroot, L.J., Jamson, J.L. (eds) Philadelphia, Saunders: 1 195-1197.
 - **British Thoracic Society(1998)** .Joint Tuberculosis Committee . Chemotherapy and management of tuberculosis in the United Kingdom: recommendations. *Thorax* ; 53:536– 548.
 - **Broad Institute. Mycobacterium tuberculosis Database(2008).** Broad Institute. Available at http://www.broad.mit.edu/annotation/genome/Mycobacterium_tuberculosis_spp/MultiHome.html. Accessed November 2008.

- **Brown AJ (2002):** Therapeutic uses of vitamin D analogues. *Am J Kidney Dis.* Nov.; 38(5Suppl 5):S3-S19.
- **Burack WR and Hollister RM(1960).** Tuberculous peritonitis. *Ann Intern Med.* ;28:510-523.
- **Burman WJ, Goldberg S, Johnson JL and et al.(2006).** Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. *Am J Respir Crit Care Med* ; 174: 331–338.
- **Butte, NF, Lopez-Alarcon, MG and Garza, C(2002).** Nutrient adequacy of exclusive breastfeeding for the term infant during the first six months of life. World Health Organization, Geneva .
- **Cain KP, Benoit SR, Winston CA and et al.(2008).** Tuberculosis among foreign-born persons in the United States. *JAMA.* ;300: 405-412.
- **Cain KP, Haley CA, Armstrong LR and et al.(2007).** Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. *Am J Respir Crit Care Med.* ;175:75-79.
- **CDC(2008).** Reported Tuberculosis in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, CDC, September .
- **Centers for Disease Control and Prevention (2009).** Web site. http://www.cdc.gov/tb/webcourses/CoreCurr/TB_Course/Menu/frameset_internet.htm. Interactive core curriculum on tuberculosis. Accessed January 28.
- **Centers for Disease Control and Prevention (CDC) and American Thoracic Society(2003)(a).** Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampicin and pyrazinamide for treatment of

- latent tuberculosis infection in United States. *MMWR* ; 52: 735–739.
- **Centers for Disease Control and Prevention(1998).** Tuberculosis morbidity—United States, 1997. *MMWR Morb Mortal Wkly Rep.* ;47:253-257.
 - **Centers for Disease Control and Prevention(2002).** Tuberculosis morbidity among U.S.-born and foreign-born populations— United States, 2000. *MMWR Morb Mortal Wkly Rep.* 2002;51:101-104.
 - **Centers for Disease Control and Prevention(2003)(b).** Treatment of tuberculosis. *MMWR Morb Mortal Wkly Rep* ; 52: 1–77.
 - **Centers for Disease Control and Prevention. American Thoracic Society(2003)(c)** CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. *MMWR* ; 52(RR-11):1–77.
 - **Centers for Disease Control(1990).** The use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. *MMWR Morb Mortal Wkly Rep.* ;39:9-12.
 - **Centers for Disease Control(1991).** Purified protein derivative (PPD) tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. *MMWR Morb Mortal Wkly Rep.* ;40:27-33.
 - **Centers for Disease Control. (1993)** Revised certification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Morb Mortal Wkly Rep.* ;41:1-19.
 - **Chambers HF, Turner J, Schecter GF and et al.(2005).** Imipenem for treatment of tuberculosis in mice and humans. *Antimicrob Agents Chemother* ; 49: 2816–2821.

- **Chambers TJ (2000)** : The origin of the osteoclast. In Peck W.A.(Eds.): Bone and mineral research. Annual 6.Amsterdam. Elsevier Science Publishers P:l.
- **Chedore P and Jamieson FB(2002).** Rapid molecular diagnosis of tuberculous meningitis using the Gen-Probe amplified Mycobacterium tuberculosis direct test in a large Canadian public health laboratory. *Int J Tuberc Lung Dis.* ;6:913-919.
- **Cheng IKP, Chan PCK and Chan MK(1989).** Tuberculous peritonitis compnopathyplicating long-term peritoneal dialysis. *Am J Nephrol.*;9:155-161.
- **Clemens, TL, Adams, JS, Henderson, SL, Holick and MF(1982).** Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. *Lancet* ; 1:74.
- **Cleve E(1954).** Atypical tuberculosis of the liver with jaundice. *Ann. Intern. Med.*; 41, 251.
- **Colditz GA, Brewer TF, Berkey CS and et al. (1994).** Effi cacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA* ; 271: 698–702.
- **Cole ST, Brosch R, Parkhill J and et al.(1998).** Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature.* ;393:537-544.
- **Conde MB, Efron A, Loredó C and et al.(2009).** Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. *Lancet* ; 373: 1183–1189.
- **Connell, TG, Curtis, N, Ranganathan, SC, Buttery and JP(2006).** Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. *Thorax* ; 61:616.

- **Cook D and Mandell L (2000):** Endotracheal aspiration in the diagnosis of ventilator associated pneumonia. *Chest*; 117: 195-197.
- **Corrigan D and Paton J(1999).** Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. *Pediatr Pulmonol* ; 27: 37-42.
- **Coulter, DS (2000):** Management of respiratory tuberculosis. *Lancet* 2000; i: 1423
- **Craig Briedly (2009):** American Journal of Respiratory and Critical Care medeciene 2007 *Am. J. Respir.* 166:176.
- **Crocco HN (2001):** Tuberculous pericarditis, A review of 100 cases . *S Afr Med j* 2001; 55:77.
- **Crofton ,J.&Douglas ,A. (1989):** Respiratory disease;4th edition. Blackwell scientific publication. Oxford ,London ,Edinburgh ,Boston ,Melbourne.
- **Cruz, AT, Starke and JR(2007).** Clinical manifestations of tuberculosis in children. *Paediatr Respir Rev* ; 8:107.
- **Cruz, AT, Starke and JR(2008).** Treatment of tuberculosis in children. *Expert Rev Anti Infect Ther* ; 6:939.
- **Daniel D. Bikle (2001):** Agents that affect bone homeostasis: Basic and clinical pharmacology, 8th ed ., 737-738.
- **Das, G, Crocombe, S, McGrath, M and et al.(2006).** Hypovitaminosis D among healthy adolescent girls attending an inner city school. *Arch Dis Child* ; 91:569.
- **Davids V, Hanekom WA, Mansoor N and et al.(2006).** The effect of bacilli Calmette-Guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. *J Infect Dis* ; 193: 531–36.

- **Davies PD, Brown RC and Woodhead JS(1985).** Serum concentrations of vitamin D metabolites in untreated tuberculosis. *Thorax* ; 40:187–190.
- **Davies PDO and Grange JM (2000):** Factors affecting susceptibility and resistance to tuberculosis. *Thorax*; 56 (suppl II): ii 23-ii29.
- **Dawson-Hughes, B, Harris, SS, Krall, EA and et al.(1995).** Rates of bone loss in postmenopausal women randomly assigned to one of two dosages of vitamin D. *Am J Clin Nutr* ; 61:1140.
- **De Sevaux RGL, Hoitsma AJ, Corstens FHM and Wetzels JFM(2002).** Treatment with vitamin D and calcium reduces bone loss after renal transplantation: A randomized study. *J Am Soc Nephrol* ;13:1608.
- **Deluca HF and Zierold C (2000):** Mechanisms and functions of Vitamin D. *Nutrition Reviews*; Feb 2000(2pt2): S4-10; discussion S54-75.
- **Dheda, K, Booth H, Huggett JF and et al.(2005).** Lung remodeling in pulmonary tuberculosis. *J Infect Dis.* ;192:1201-1210.
- **Dhingra VK(2006).** Treatment of tuberculosis in liver disease (A clinician's view). *Indian J Tuberc* ; 53: 232-233.
- **Diacon AH, Pym A, Grobusch M and et al.(2009).** The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N Engl J Med* ; 360: 2397–2405.
- **Dixon PH, Christie PT, Wooding C, Trump D, Grieff M, Holm I, Gertner JM, Schmidtke J, Shah B, Shaw N, Smith C, Tau C Schleissinger D, Whyte Mp and Thakker RV (2003):** Nutational analysis of PHEX gene in X-linked hypophosphatemia. *J Clin Endocrinal Metab.* Oct.;83(10): 3615-23

- **Doherty TM, Dietrich J and Billeskov R(2007).** Tuberculosis subunit vaccines: from basic science to clinical testing. *Expert Opin Biol Ther* ;7: 1539–49.
- **Donald PR(2007).** The assessment of new anti-tuberculosis drugs for a paediatric indication. *Int J Tuberc Lung Dis* 2007; **11**: 1162–65.
- **Donald PR, Maher D, Maritz JS and Qazi S(2006).** Ethambutol dosage for the treatment of children: literature review and recommendations. *Int J Tuberc Lung Dis* ; 10: 1318–30.
- **Donald PR, Schoeman JF and O'Kennedy A(1987).** Hepatic toxicity during chemotherapy for severe tuberculosis meningitis. *Am J Dis Child* 1; 141: 741-3.
- **Donald PR, Seifart HI, Parkin DP and van Jaarsveld PP(1994).** Hydrazine production in children receiving isoniazid for the treatment of tuberculous meningitis. *Ann Pharmacother* ; 28:1340-3.
- **Donald, PR, Maher, D, Maritz, JS and Qazi, S(2006).** Ethambutol dosage for the treatment of children: literature review and recommendations. *Int J Tuberc Lung Dis* ; 10:1318.
- **Donfield AM, Watt CJ and Williams BG (2005):** The growing burden of tuberculosis. *Arch Intern Med* 2005, 163:1009-1021.
- **Dorman SE, Johnson JL, Goldberg S and et al.(2009).** Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. *Am J Respir Crit Care Med* ; 180: 273–280.
- **Dossing M, Wilcke JT, Askgaard DS and Nybo B(1996).** Liver injury during antituberculosis treatment: an 11-year study. *Tuber Lung Dis* ; 77: 335–340.

-
- **Doyle R, Goldberg K, Harold CE and Poeggl J (2002):** Handbook of pediatric drug therapy. 2nd ed., Springhouse, Pennsylvania: Springhouse corporation: 295-297.
 - **Drobac PC, Mukherjee JS, Joseph JK and et al.(2006).** Community-based therapy for children with multidrug-resistant tuberculosis. *Pediatrics*; **117**: 2022–29.
 - **Drug facts and comparisons (2002):** Diuretics . 56th ed., St. Louis: Facts and Comparisons, A Wolters Kluwer Company: 663-667.
 - **Dube MP, Holtom PD and Larsen RA(1992).** Tuberculous meningitis in patients with and without human immunodeficiency virus infection. *Am J Med.* ;93:520-524.
 - **Durand F, Jebrak G, Pessayre D, Fournier M and Bernuau J(1996).** Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. *Drug Saf* ; 15: 394-405.
 - **Ena J and Valls V(2005).** Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. *Clin Infect Dis* 2005; 40: 670–76.
 - **Enarson D, Rieder H, Arnadottir T and Tre´bucq A(2000).** Management of tuberculosis: a guide for low income countries, 5th ed. Paris: International Union Against Tuberculosis and Lung Disease;. Available from:http://www.iatld.org/pdf/en/guides_publications/management_of_tb.pdf
 - **Ernst JD, Trevejo-Nunez G and Banaiee N(2007).** Genomics and the evolution, pathogenesis, and diagnosis of tuberculosis. *J Clin Invest.*2007;117:1738-1745.
-

- **Essop AR, Posen JA, Hodgkinson JH and Segal I(1984).** Tuberculosis hepatitis: a clinical review of 96 cases. *QJ Med* ; 53: 465- 477.
- **Euro TB(2005).** Surveillance of tuberculosis in Europe—EuroTB. Report on tuberculosis cases notified in 2005. http://www.eurotb.org/rapports/2005/full_report.pdf (accessed June 19, 2008).
- **Evans JT, Smith EG, Banerjee A and et al(2007).** Cluster of human tuberculosis caused by *Mycobacterium bovis*: evidence for person-to-person transmission in the UK. *Lancet.* ;369:1270-1276.
- **Ewer K, Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S and Namujju PB, (2007).** A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. *J Infect Dis* 2004;190:869–878.
- **Fauci, A.S., Lane and H.C(1991).** The acquired immunodeficiency syndrome. In Wilson J.D. et al. (eds) *Harrison's principles of internal medicine*, 12th ed. McGraw Hill, New York; p. 1402.
- **Feldman, D. (2003):** Parathyroid hormone and calcium , a complex regulatory network .*American Journal of medicine*, 107:637.
- **Ferguson JS, Weis JJ, Martin JL and Schlesinger LS(2004).** Complement protein C3 binding to *Mycobacterium tuberculosis* is initiated by
- **Fernandez-Rodriguez CM, Perez-Arguelles BS, Ledo L and et al.(1991).** Ascites adenosine deaminase activity is decreased in tuberculous ascites with low protein content. *Am J Gastroenterol.* ;86:1500-1503.

- **Fine PE(1995).** Variation in protection by BCG: implications of and for heterologous immunity. *Lancet* ; **346**: 1339–45.
- **Fishman JA: Fishman AP, Elias JA, Fishman JA, et al. (eds) (2002):** Mycobacterial infections in Fishman's manual of pulmonary diseases and disorders. 3rd edition. McGraw-Hill. North America:763-819.
- **Fortun J, Johnson J and Nelson (2005):** Linezolid for the treatment of multi- drug resistant tuberculosis, *J antimicrob chemother* .2005; 56 : 180: 185
- **Fournier A,Oprisiu R,Hottelart C,Yverneau PH,Ghazali A, Atik A, Hedri H, Said S, Sechet A,Rasomboholona M,Abighanem O, Sarraj A, El Esper N, Morniere P, Boudailliez B, Westell PF, Achard JM and Pruna A (2000):** Renal osteodystrophy in dialysis patients : diagnosis and treatment. *Artif Organs* Jul.; 22(7):530-57 .
- **Fraser RG, Pare JAP, Pare PD and et al.(2001):** Diagnosis of Diseases of the Chest, ed 3, pp 885-933. WB Saunders, Philadelphia, .
- **Fraser, D, Scriver and CR(1979).** Hereditary disorders associated with vitamin-D resistance or defective phosphate metabolism. In: *Endocrinology*, DeGroot, LJ (Ed), Grune & Stratton, New York . p.797.
- **Frieden TR, Sterling TR, Munsiff SS, Watt CJ and Dye C(2003).** Tuberculosis. *Lancet* .;362:887-899.
- **Frontera Izquierdo P, Unceta Aguirre L, Tomás Vila M, Calvo Rigual F and Pérez Tamarit D(1981).**Hepatotoxicity of rifampicin and isoniazid in the treatment of tuberculous meningitis (author's transl). [Article in Spanish]. *An Esp Pediatr* ; 15: 549-52

- **Gandhi NR, Moll A, Sturm AW and et al.(2006).** Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006; 368: 1575–80.
- **Garabedian, M.; Balsan, S. and David, L. (2000):** Calcium and Phosphorus metabolism and disorders parathyroid hormone, vitamin D and calctonin. In: *Pediatric Endocrinology*. Bertrand, J.; Rappaport, R.; and sizioneko, P.C. (Eds), 2nd edition. Williams and Wilkins, Baltimore, Philadelphia, Hong kong, London, Munich, Sydney, Tokyo; P496-507.
- **Garnier T, Eiglmeier K, Camus JC and et al.(2003).** The complete genome sequence of *Mycobacterium bovis*. *Proc Natl Acad Sci U S A* ;100:7877-7882.
- **Gartner, LM, Morton, J, Lawrence, RA and et al.(2005).** Breastfeeding and the use of human milk. *Pediatrics*; 115:496.
- **Gendrel D, Nardou M, Mouba JF, Gahouma D, Moussavou A and Boguikouma JB(1989).** Hepatotoxicity of the combination of isoniazid-rifampicin in African children. Role of malnutrition and HB virus [Article in French]. *Arch Fr Pediatr* ; 46: 645-8.
- **Gie, RP, Beyers, N, Schaaf, HS and Goussard, P(2004).** The challenge of diagnosing tuberculosis in children: a perspective from a high incidence area. *Paediatr Respir Rev* ; 5 Suppl A:S147.
- **Glerup, H, Mikkelsen, K, Poulsen, L and et al.(2000).** Commonly recommended daily intake of vitamin D is not sufficient if sunlight exposure is limited. *J Intern Med* ; 247:260.
- **Gordin FM, Matts J, Miller C and et al.(1997).** A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. *N Engl J Med*. ;337:315-320.

- **Gordon, CM, DePeter, KC, Feldman, HA and et al(2004).** Prevalence of vitamin D deficiency among healthy adolescents. *Arch Pediatr Adolesc Med* ; 158:531.
- **Goyot-Revol V, Innes JA, Hackforth S, Hinks T and Lalvani A(2006).** Regulatory T cells are expanded in blood and disease sites in patients with tuberculosis. *Am J Resp Crit Care Med.* ;173:803-810.
- **Grang,J.M.;Davies ,P.D.O. ; Brown,R.C.; Woodhead,J.S. &Kardjito, T. (1985):** Astudy of vit.D level in Indonesian patient with untreated pulmonary T.B. *Tubercle* 66(1985) 187-191.
- **GrayZbowski S.2000.** Tuberculosis in the third world. *Thorax* 2000; 46:689.
- **Grzybowski S, Allen EA(1964).** The challenge of tuberculosis in decline: a study based on the epidemiology of tuberculosis in Ontario,Canada. *Am Rev Respir Dis.* ;90:707-720.
- **Guidance for National Tuberculosis Programmes (2006)**on the management of tuberculosis in children. Chapter 1: introduction and diagnosis of tuberculosis in children.; 10:1091.
- **Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkeköl FO, Baççioğlu A and et al.(2006).** Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. *Respir Med* ; 100:1834-42.
- **Gurkan F, Bosnak M, Dikici B and et al(1998).** Miliary tuberculosis in children: a clinical review. *Scand J Infect Dis* ;30:359-62.
- **Gusmão Filho FA, Marques-Dias MJ, Marques HH and Ramos SR(2001).** Central nervous system tuberculosis in children: 2. Treatment and outcome. [Article in French] *Arq Neuropsiquiatr* ; 59: 77-82.

- **Gutierrez MC, Brisse S, Brosch R and et al.(2005).** Ancient origin and gene mosaicism of the progenitor of *Mycobacterium tuberculosis*. *PLoS Pathog.* ;1:e5.
- **Haas DW(1998).** Are adjunctive corticosteroids indicated during tuberculous peritonitis? *Clin Infect Dis.* ;27:57-58.
- **Haussler MR and Whitfield GK (2000):** The nuclear vitamin D receptor: Biological and Molecular Regulatory Properties Revealed. *J Bone Miner. Res.*, 13:325.
- **Havlir DV and Barnes PF(1999).** Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med.* ; 340:367-373.
- **Hawkey CR, Yap T, Pereira J and et al.(2005).** Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. *Clin Infect Dis*; 40: 1368–1371.
- **Henry, HL, Norman and AW(1974).** Studies on calciferol metabolism. IX. Renal 25-hydroxy-vitamin D₃-1 hydroxylase. Involvement of cytochrome P-450 and other properties. *J Biol Chem* ; 249:7529.
- **Hersch, C(1964).** Tuberculosis of the liver. *South Afr. Med. J.*; 38, 857.
- **Hesseling AC, Cotton MF, Marais BJ and et al.(2007).** BCG and HIV reconsidered: moving the research agenda forward. *Vaccine* ;25: 6565–68.
- **Hesseling AC, Marais BJ, Gie RP and et al.(2007).** The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. *Vaccine* ; 25: 14–18.
- **Holdiness MR(1987).** Transplacental pharmacokinetics of the antituberculous drugs. *Clin Pharmacokinet* ;13:125–9.

- **Holick, M.F. (ed) (2000):** Vitamin D-physiology : Molecular Biology and Clinical Application , Totowa , N.J Humana Press , 25-30 .
- **Holick, MF(2007).** Vitamin D deficiency. *N Engl J Med*; 357:266.
- **Holick, MF, Krane, SM, Potts and JT(1995).** Calcium, Phosphorous, and Bone Metabolism: Calcium-regulation hormones. In *Harrison's principles of internal medicine*, 14th edition, Fauci, AS, Braunwald, E, Isselbacher, KJ, et al (Eds), McGraw-Hill, New York . p.2214.
- **Hollis, BW, Wagner and CL(2004).** Assessment of dietary vitamin D requirements during pregnancy and lactation. *Am J Clin Nutr* ; 79:717.
- **Hollis, BW, Wagner and CL(2004).** Vitamin D requirements during lactation: high-dose maternal supplementation as therapy to prevent hypovitaminosis D for both the mother and the nursing infant. *Am J Clin Nutr* ; 80:1752S.
- **Hursey G, Chisholm T and Kibiel M(1991).** Miliary tuberculosis in children: A review of 94 cases. *Pediatr Infect Dis J* ; 10: 832-836.
- **Infectious Diseases and Immunization Committee(1994),** Canadian Paediatric Society. Short-course therapy for tuberculosis in infants and children. *Can Med Assoc J* ; 150:1233-39.
- ***Int J Tuberc Lung Dis* (2006):**Guidance for national tuberculosis programmes on the management of tuberculosis in children. Chapter 2: anti-tuberculosis treatment in children.; 10: 1205–11
- **Jakubowski A, Elwood RK and Enarson DA(2002).** Clinical features of abdominal tuberculosis. *J Infect Dis.*;158:687-692.
- **Jakubowski A, Elwood RK and Enarson DA.(2002)** Clinical features of abdominal tuberculosis. *J Infect Dis.* ;158:687-692.

- **Jasmer RM and Daley CL(2003).** Rifampicin and pyrazinamide for treatment of latent tuberculosis infection: is it safe. *Am J Respir Crit Care Med* 2003; 167:809–810.
- **Jensen PA, Lambert LA, Iademarco MF and Ridzon R; Centers for Disease Control and Prevention(2005).** Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care settings, 2005. *MMWR Recomm Rep.* ;54(RR-17):1-141.
- **Jereb JA, Kelly GD, Dooley SW and et al.(1991).** Tuberculosis morbidity in the United States: final data, 1990. *MMWR Morb Mortal Wkly Rep.* 1991;40:23-27.
- **Johnson MP, Coberly JS, Clermont HC and et al.(1992).** Tuberculin skin test reactivity among adults infected with human immunodeficiency virus. *J Infect Dis.* ;166:194-198.
- **Johri, B.S., Kane, M.P., Mudbhatkal and N.S(1970).** Isolated tuberculosis of the liver. *Indian J. Med. Sci.*; 24, 16.
- **Kaneko Y, Nagayama N, Kawabe Y, Shimada M, Suzuki J, Kunogi M and et al.(2008).** Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis [Article in Japanese] *Kekkaku* ; 83:13-9
- **Kang YA, Lee HW, Hwang SS and et al. (2008):** "Usefulness of Whole-Blood Interferon- γ Assay and Interferon- γ Enzyme-Linked Immunospot Assay in the Diagnosis of Active Pulmonary Tuberculosis". *Chest* 132 (3): 959-65.
- **Karalliede S, Katugha LP and Uragoda CG(1987).** The tuberculin response of Sri Lankan children after BCG vaccination at birth. *Tubercle* ;68:33-8.
- **Kaur A, Basha A, Ranjan M and Oommen A(1992).** Poor diagnostic value of adenosine deaminase in pleural, peritoneal &

cerebrospinal fluids in tuberculosis. *Indian J Med Res.* ;95:270-277.

- **Kawamori, Y., Matsui, O., Kitagawa, K. and et al.(1992).** Macronodular tuberculoma of the liver : CT and MR findings. *A.J.R.*; 158, 311.
- **Kennedy DH and Fallon RJ.(2003)** Tuberculous meningitis. *JAMA.* ;241:264-268.
- **Kielhofner MA and Hamill RJ(1991).** Focal hepatic tuberculosis in a patient with acquired immunodeficiency syndrome. *South Med J.* ;84:401-404.
- **Kopanoff DE, Snider DE Jr and Caras GJ(1978).** Isoniazid-related hepatitis. *Am Rev Respir Dis* ; 117: 991-1001.
- **Korf JE, Pynaert G, Tournoy K and et al.(2006).** Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma. *Am J Respir Crit Care Med.*;174(2):152-160.
- **Kragballe, (2000):** Vitamin D in Dermatology, edited by Knud Kragballe
- **Kruse K and Feldman E (2000):** Healing of rickets during vitamin D therapy despite defective vitamin D receptors in two siblings with vitamin D-dependant rickets type II. *J Pediatr.* Jan.; 126(1): 145-8.
- **Kumar A, Misra PK, Mehotra R, Govil YC and Rana GS(1991).**Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis? *Am Rev Respir Dis* 1991; 143:1350-2.
- **Kumar D, Waston JM and Nicholas S (2000):** Tuberculosis in England and Wales in Results of anational survey. *Eur Respiriv* 2001; 9:1097.

- **Kumar Vinay, Abbas Abul K, Fausto Nelson and Mitchell, Richard N. (2007):** Robbins Basic Pathology (8th ed.). Saunders Elsevier, pp. 516-522.
- **Laibl, VR and Sheffield, JS(2005).** Tuberculosis in pregnancy. Clin Perinatol ; 32:739.
- **Lannatti, J.P (2001):** Growth plate physiology and pathology. Ortho. Clin. N.Am.; 21(1):345.
- **Lapthorn,A Sita-Lumsden, R Swaminathan and H J Milburn(2007)** Thorax;62:1003-1007 Published Online First: 25 May 2007 doi:10.1136/thx.2006.070060
- **Leader, S.A(1952).** Tuberculosis of the liver and gall bladder with abscess formation : A review and case report. Ann. Intern. Med.; 37,594.
- **Li Y, Petrofsky M and Bermudez LE(2002).** Mycobacterium tuberculosis uptake by recipient host macrophages is influenced by environmental conditions in the granuloma of the infectious individual and is associated with impaired production of interleukin-12 and tumor necrosis factor alpha. *Infect Immun.*;70:6223-6230.
- **Lienhardt C, Vernon A and Raviglione MC(2010).** New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med ; 16: 186–193.
- **Lighter, J and Rigaud, M(2009).** Diagnosing childhood tuberculosis: traditional and innovative modalities. Curr Probl Pediatr Adolesc Health Care ; 39:61.
- **Lillington, G.A. &Jamplis, D. (1977):** A diagnostic approach to chest diseases . Differential diagnosis based on roentgenographic

patterns. 2nd ed. P.210. The Williams & Wilkins company , Baltimore .

- **Linna O and Uhari M(1985).** Hepatotoxicity of rifampicin and isoniazid in children treated for tuberculosis. *Pediatr Infect Dis*; 4: 270-3.
- **Lips, P, Hosking, D, Lippuner, K and et al.(2006).** The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. *J Intern Med* ; 260:245.
- **Liu PT, Stenger S, Tang DH and et al.(2007).** Cutting edge: vitamin D mediated human antimicrobial activity against *Mycobacterium tuberculosis* is dependent on the induction of cathelicidin. *J Immunol* ; 179: 2060–2063.
- **Lobato, MN, Loeffler, AM, Furst, K and et al.(1998).** Detection of *Mycobacterium tuberculosis* in gastric aspirates collected from children: hospitalization is not necessary. *Pediatrics* ; 102:E40.
- **Lok AS and McMahon BJ. (2004):** Practice Guidelines Committee American Association for the Study of Liver Diseases. Chronic hepatitis B: update of recommendations. *Hepatology* ; 39: 857–861.
- **Looker AC, Pfeiffer CM, Lacher DA, Schleicher RL, Picciano MF and Yetley EA(2008).** Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. *Am J Clin Nutr*;88:1519–27.
- **Mack U, Migliori GB, Sester M and et al.(2009).** LTBI: latent tuberculosis infection or lasting immune responses to *M. tuberculosis*? A TBNET consensus statement. *Eur Respir J*; 33: 956–973.

- **Maglinte DD ,Alvarez SZ ,Ng Ac and et al. (1988).**Pattern of calcifications and cholangiographic findings in hepatobiliary tuberculosis .Gastrointest. Radiol .;13:331-335.
- **Mahajan M, Rohatgi D, Talwar V, Patni SK, Mahajan P and Agarwal DS(1997).** Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis. Commun Dis ; 29: 269-74
- **Maharaj, B., Leary, W.P. and Pudifin, D.J(1987).** A prospective study of hepatic tuberculosis in 41 black patients. Quart. J. Med.; 63,517.
- **Malhotra I, Mungai P, Wamachi A and et al.(1999).** Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. *J Immunol* ; 162: 6843–48.
- **Mandella F, Villani A, Merolla R, Bjermer L, Sandstrom T and Ronchetti R (2000):** Bronchalveolar lavage studies in children without parenchymal lung diseases: cellular constituents and protein levels. *Pediatr Pulmonol.*; 20: 112-118.
- **Manji, KP, Msemu, G, Tamim, B and Thomas, E(2001).** Tuberculosis (presumed congenital) in a neonatal unit in Dar-es-Salaam, Tanzania. *J Trop Pediatr* ; 47:153.
- **Marais, BJ, Gie, RP, Hesselning, AC and et al.(2006).** Radiographic signs and symptoms in children treated for tuberculosis: possible implications for symptom-based screening in resource-limited settings. *Pediatr Infect Dis J* ; 25:237.
- **Marais, BJ, Gie, RP, Schaaf, HS and et al.(2006).** Childhood pulmonary tuberculosis: old wisdom and new challenges. *Am J Respir Crit Care Med* ; 173:1078.

- **Marcus R (2001):** Agents affecting calcification and bone turnover. Calcium, Phosphate, Parathyroid, hormone, vitamin D, calcitonin and other compounds. In, Hardman JG, Limbird LE and Gilman Ag (eds.), Goodman and Gilman's The pharmacological basis of therapeutics. 10th ed., ch.62, New York: McGraw-Hill: 716-1743.
- **Martin KJ and Gonzaler EA (2001):** Strategies to minimize bone disease in renal failure. Am J Kidney Dis. Dec.; 138(6): 1430-1460.
- **Martineau AR WK, Newton SM, Floto RA and et al.(2007).** IFN-c- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol ; 178:7190–7198.
- **Martineau AR, Peter MT, Graham HB and et al.(2011).** High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet ; 377: 242–250.
- **Martinez-Roíg A, Camí J, Llorens-Terol J, de la Torre R and Perich F(1986).** Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics ; 77: 912-5.
- **Mayosi BM, Ntsekhe M, Volmink JA and et al.(2002).** Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev ; 4: CD000526.
- **Mazouni SM(1986).** Short-course chemotherapy (6 months) for respiratory tuberculosis in children: results at 30 months. Bull Int Union Tuberc ; 61: 16–7.
- **Mazurek, GH, Jereb, J, Lobue, P and et al.(2005).** Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep ; 54:49.

- **McCracken GH Jr(2000).** Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. *Clin Infect Dis* 2000; 31 (Suppl 2):S45-50.
- **McNally MD, Karen Leis MD and Alan M. Rosenberg MD(2008).** *Pediatric Pulmonology* Volume 44, Issue 10, pages 981–988, October 2009.
- **Meintjes G, Lawn SD, Scano F and et al.(2008).** Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect Dis* ; 8:516–523.
- **Menzies D (2003):** Sputum induction: Simple, Cheaper and Safer....But Is It Better? *Am J Respir Crit Care Med*, March; 167 (5): 676-77.
- **Menzies D(2000).** What does tuberculin reactivity after bacilli Calmette-Guerin vaccination tell us? *Clin Infect Dis.* ;31:S71-S74.
- **Menzies D, Pai M and Comstock G (2007):** "Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research". *Ann. Intern. Med.* 146 (5): 340-54.
- **Mezies R and Vissandjee B(1992).** Effect of Bacille Calmette-Guérin vaccination on tuberculin reactivity. *Am Rev Respir Dis* ;145:621-5.
- **Micheal F, Holick and Stephan M. Krane (2001):** Disorder of bone and mineral metabolism : *Harrison's Principles of internal Medicine*, 15th ed.,2201. and 2196- 2197.
- **Migliori GB, Eker B, Richardson MD and et al.(2009).** A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. *Eur Respir J* ; 34: 387–393.

- **Mishra S, Yadav Tp, Nangia S, Gupta Vk and Sidhu KK (2000):** Vitamin D-dependant rickets type II. *Indian Pediatr.* Apr.; 33(4): 334-6.
- **Mishu Allos B, Gensheimer KF, Bloch AB and et al.(1996).** Management of an outbreak of tuberculosis in a small community. *Ann Intern Med.* ;125:114-117.
- **Misra, M, Pacaud, D, Petryk, A and et al.(2008).** Vitamin D deficiency in children and its management: review of current knowledge and recommendations. *Pediatrics* ; 122:398.
- **Modern Medicine(1994).** Watch carefully for hepatotoxicity when using anti-TB drugs.; 62(8).
- **Morb Mortal Wkly Rep (MMWR) (2009).** Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis.; 58:7.
- **Morb Mortal Wkly Rep(MMWR).(2008).** Trends in tuberculosis—United States, 2007.;57:281-285.
- **Morgan, SL and Weinsier(1998), RL** Fundamentals of clinical nutrition. Mosby, St Louis . p.3.
- **Munoz FM and Starke JR (2004):** Tuberculosis. In: Beherman RE, kliegman RM and Jenson HB (eds). *Nelson text book of Pediatrics.* 17th edition. Saunders. Philadelphia, Pennsylvania. USA: 958-972.
- **Murthy GD, Byron D, Shoemaker D, Visweswaraiah H and Pasquale D(2001).** The utility of rifampicin in diagnosing Gilbert's syndrome. *Am J Gastroenterol* ; 96:1150–1154.
- **Napoli, N.E. Carmina and et al. (2006):** Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. *Bone* 38(6): 888-892.

- **Nash DR and Douglass JE(1980).** Anergy in active pulmonary tuberculosis: a comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses. *Chest.* ;77:32-37.
- **Nathwani RA and Kaplowitz K(2006).** Drug Hepatotoxicity. *Clin Liver Dis* ; 10: 207-217.
- **National Academies Press and Washington DC (1998).** National Research Council Recommended dietary allowances, 10th edition .
- **National Academies Press and Washington DC (2000).** Food and Nutrition Board of the Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, fluoride. p. 250-287. Available at:
http://books.nap.edu/catalog.php?record_id=5776 (Accessed 7/23/07).
- **Nelson LJ, Schneider E, Wells CD and Moore M(2004).** Epidemiology of childhood tuberculosis in the United States, 1993–2001: the need for continued vigilance. *Pediatrics* ; **114**: 333–41.
- **Nicod LP(2007).** Immunology of tuberculosis. *Swiss Med Wkly.* ;137(25-26):357-362.
- **Nnoaham KE and Clarke A(2008).** Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. *Int J Epidemiol* ; 37: 113–119.
- **Nolan and R.J.JR.(1986).** Childhood tuberculosis in north Carolina .A study of opportunities for intervention in the transmission of tuberculosis of children .*Am.J.Public health* , January 1986 vol.76 ,(1):26-30.
- **Nursyam EW, Amin Z and Rumende CM(2006).** The effect of vitamin D as supplementary treatment in patients with moderately

- advanced pulmonary tuberculous lesion. *Acta Med Indones*; 38: 3–5.
- **Nwonwu E U, P G Oyibo, A O C Imo, C D Ndukwe, C N Obionu, and C J Uneke(2008)** : Radiological features of pulmonary tuberculosis in HIV-positive and HIV-negative adult patients in south-eastern Nigeria.
 - **Nyendak MR ,Lewinsohn DA and Lewinsohn DM (2009).**New diagnostic methods for tuberculosis .*Curr.Opin.Infect.Dis.*;22:174-182 .
 - **O'Brien RJ, Long MW, Cross FS, Lyle MA and Snider DE Jr.(1983)** Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. *Pediatrics* ; 72: 491-9.
 - **Oh P, Granich R, Scott J and et al.(2002).** Human exposure following *Mycobacterium tuberculosis* infection of multiple animal species in a metropolitan zoo. *Emerg Infect Dis.* ;8:1290-1293.
 - **Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S and et al.(2002).** Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. *Clin Pharmacol Ther* ; 72: 220-6.
 - **Oliva, A. Duarte, B., Jonasson, O. and Nadimpalli, V(1990).** The nodular form of local hepatic tuberculosis. *J. Clin. Gastroenterol*; 12, 166.
 - **Owens, S, Abdel-Rahman, IE, Balyejusa, S and et al.(2007).** Nasopharyngeal aspiration for diagnosis of pulmonary tuberculosis. *Arch Dis Child* ; 92:693.
 - **Oyer A and Schlossber D(2000):** Hematologic changes in tuberculosis. In: *Tuberculosis and non tuberculous mycobacterial infections*. Oyer A and Schlossber D (eds.);4th ed. WB Saunders, chap 9: 98-103

- **Pai, M, Zwerling, A and Menzies, D(2008).** Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. *Ann Intern Med* ; 149:177.
- **Pakasi TA, Karyadi E, Dolmans WM and et al. (2009).** Malnutrition and socio-demographic factors associated with pulmonary tuberculosis in Timor and Rote Islands, Indonesia, *Int J Tuberc Lung Dis* 2009 Jun; 13(6) :755-9.
- **Palusci V J, O'Hare D and Lawrence R M(1995).** Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. *Pediatr Infect Dis J* ; 14: 144–148.
- **Parfitt K (2000):** Vitamin D. In Martindale, The complete drug reference. 32nd ed., Taunton, Massachussets: Pharmaceutical Press: 1366-1369.
- **Park IN and Oh YM (2006):** Efficacy of daily-half dose Linezolid in patient with intractable MDRTB, *J antimicrob chemother* 2006 ; 58: 701: 704.
- **Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S and et al.(1986).** Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide *Tubercle.* ; 67: 99-108
- **Peloquin CA(2002).** Therapeutic drug monitoring in the treatment of tuberculosis. *Drugs* ; 62: 2169-83.
- **Pereira, L(2004).** Tuberculosis: role of etiologic diagnosis and tuberculin skin test. *Pediatr Pulmonol Suppl* ; 26:240.
- **Pettifor JM, Bikle DD, Cavaleros M, Zachen D, Kamdar M and Ross FP (2002):** Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity . *Ann Intern Med.* April; 122(7):511-3.

- **Pierre C, Oliver C and Yeni P (2001):** Diagnosis of Primary tuberculosis in children. *Am Rev Respir Dis* 2001; 142: 147.
- **Plumber, S.T., Pipalia, D.H., Vora, I.M., Bhambhure, N. and Naik, S.R(1987).** Hepatic granulomas: Profile and follow up of 10 cases responding to antituberculous therapy. *J. Assoc. Physician India*; 35, 207.
- **Porth CM(2002).** Alterations in respiratory function: respiratory tract infections, neoplasms, and childhood disorders. In: Porth CM, Kunert MP. *Pathophysiology: Concepts of Altered Health States*. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:615-619.
- **Pottipati, A.R., Dave, P.B., Gumaste, V. and Vieux, U(1991).** Tuberculous abscess of the liver in acquired immunodeficiency syndrome. *J. Clin. Gastroenterol*; 13,549.
- **Pouchot J, Grasland A, Collet C and et al.(1997).** Reliability of tuberculin skin test measurement. *Ann Intern Med.* ;126:210-214.
- **Powell DA and Hunt WG(2006).** Tuberculosis in Children: An Update. *Adv Pediatr* ; 53: 279-322.
- **Ramakrishna B and Date A(1993).** Pattern of liver disease in children: A review of 128 biopsied cases. *Ann Trop Pediatr* ; 13: 159-163.
- **Rapp RS, Campbell RW, Howell JC and Kendig EL Jr(1978).** Isoniazid hepatotoxicity in children. *Am Rev Respir Dis* ; 118: 794-6.
- **Reddy VM (2002):** Antituberculosis activity of clarithromycin, *J antimicrob chemother* 2000; 39 2692 : 2695
- **Reichel H, Koeffler HP and Norman AW (2001):** The role of the vitamin D endocrine system in health and disease. *N Engl J Med* 320:980-991.

- **Reto Valiente LV, Castillo Vergara J, Pichilingue Reto P and Pichilingue Prieto OA(2005)** : Hepatotoxicity caused by antituberculosis drugs in pediatrics [Article in Spanish] *Rev Gastroenterol Peru* 2005; 25:362-5.
- **Reynolds, T.B., Campra, J.L. and Peters, R.L(1990)** : Hepatic granulomata. In Zakim D, Boyer T.D. (eds.) *Hepatology - A textbook of liver disease*, 2nd ed. W.B. Saunders, Philadelphia; p. 1098.
- **Rheenen PV (2002):** The use of pediatric tuberculosis score chart in an HIV -endemic area. *Tropical Medicine and International Health*, May; 7(5): 435- 445.
- **Rieder, H.L., Cauthen G.M., Bloch,, A.B. and et al.(1989).** Tuberculosis and acquired immunodeficiency syndrome. *Arch. Intern. Med.*; 149,1268.
- **Robert J, Rikke Olesen, Paulo Rabna and Pernille Kaestel, (2009):** *American Journal of Clinical Nutrition*, Vol. 86, No. 5, 1376-1383, November 2009.
- **Rodrigues LC, Diwan VK and Wheeler JG(1993).** Protective effect of BCG against tuberculous meningitis and miliary tuberculosis:a meta-analysis. *Int J Epidemiol*; 22: 1154–58.
- **Rodrigues LC, Pereira SM, Cunha SS and et al.(2005).** Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. *Lancet* ;366: 1290–95.
- **Root AW (2000):** Parathyroid glands, calcium, phosphorus and vitamin D metabolism. In *clinical pediatric Endocrinology*. Hung, W. (Ed), Mosby Year Book, St. Louis, Baltimore, Boston, Chicago, London, Philadelphia, Sydney, Toronto. P:89-124.

-
-
- **Rosengart, T.K. and Coppa G.F(1990).** Abdominal mycobacterium infections in immunocomprised patients. *Am. J. Surg.*;159,125.
 - **Rosenkrands I, Slayden RA, Crawford J and et al.(2002).** Hypoxic response of Mycobacteria tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. *J Bacteriol.* ;184:3485-3491.
 - **Roth A, Garly ML, Jensen H, Nielsen J and Aaby P(2007).** Bacillus Calmette-Guerin vaccination and infant mortality. *Expert Rev Vaccines* ; 5: 277–93.
 - **Roy V, Tekur U and Chopra K(1996).** Pharmacokinetics of isoniazid in pulmonary tuberculosis – a comparative study at two dose levels. *Indian Pediatr* ; 33: 287–91.
 - **Russell and W.Cheseny (2000):** Metabolic Bone Disease: Nelson Text of Pediatric , 16th ed ; 2134-2138.
 - **Sáez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD and et al.(2002).** Trovan meningitis Study Group. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. *Pediatr Infect Dis J* ; 21:14-22.
 - **Sahn SA and Neff TA(2002):** Miliary tuberculosis. *Am J Med* 109:554-560, .
 - **Saigal S, Agarwal SR, Nandeesh HP and Sarin SK(2001).** Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: A preliminary report. *J Gastroenterol Hepatol* ; 16: 1028-32.
 - **Sakr,R.; Habib ,A.;Samuel,S.; Tawadros,G.A. and El Mohandes,A.(1986):** Studies on absorptive functions in chronic

debilitating diseases in children.

Reprint from Gaz.Egypt.Ped.Ass.,34:1-4.

- **Sakr,r.;Samuel,S. ;El Heneidy,F.&Attalla,A.L.(1981) :**Clinico-radiological diagnosis of tuberculous lymphadenopathy versus pathological diagnosis. Gaz,Egypt.ped. Ass.Vol.29No.1-2,Jan.-April 1981;151-161.
- **Sakr,R.;Samuel,S.;Helmy and N.T.(1984):** Studies on extrapulmonary T.B. in Egyptian children. The Egyptian Journal of chest disease &tuberculosis. Vol.27 no. IP:157-165.
- **Samuel ,S.W.;Safwat,M.&El Ghamrawy T.A.(1995):** Aprospective study on patients attending the chest clinic in the pediatric hospital,Cairo university.Msc. thesis
- **Samuel,S. ;Sakr,R.;Mohamed,A.A.; Ibrahim,A.M.; Eyada,T.K.and Abdel Hamid,A.(1986):** Some cytochemical studies on ciculating polymorphnuclear leucocytes in tuberculous infants and children. The Egypt.J. Haemat. Vol.11 N° 3-4,233-244,1986.
- **Samuel,S.;Kotb,A.;Maher,R.A.;Hegazi,M.I.&Saber,W.M. (1990)** Study of some macroµ elements & their relation to nutritional status in T.B. children . Faculty of medicine,Cairo university;M.D. thesis.
- **Sánchez-Albisua I, Vidal ML, Joya-Verde G, del Castillo F, de José MI and García-Hortelano J(1997).** Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. *Pediatr Infect Dis J* ;16: 760-3.
- **Sasidharan PK and Villamor E (2003):** Effect of vitamin D supplementation on immune response and correlation with clinical outcome. *Am J Clin Nutr* 68, 425S-429S.

- **Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM and et al.(2006).** Hepatotoxicity of Antituberculosis Therapy. *Am J Respir Crit Care Med* ; 174:935-52.
- **Savage M (2001):** Complications with reformulated one-alpha vitamin D.BMJ 322 (7289):799.
- **Schaaf HS, Marais BJ, Whitelaw A and et al.(2007).** Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. *BMC Infect Dis* ; 7: 140.
- **Schaaf HS, Parkin DP, Seifart HI and et al.(2005).** Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. *Arch Dis Child* ; 90: 614–18.
- **Schaaf HS, Shean K and Donald PR(2003).** Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. *Arch Dis Child* ; 88: 1106–11.
- **Schaaf, HS, Beyers, N, Gie, RP and et al.(1995).** Respiratory tuberculosis in childhood: the diagnostic value of clinical features and special investigations. *Pediatr Infect Dis J* ; 14:189.
- **Schoeman JF, Van Zyl LE, Laubscher JA and Donald PR(1997).** Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. *Pediatrics* ; 99: 226–31.
- **Seth V and Beotra A(1989).** Hepatic function in relation to acetylator phenotype in children treated with antitubercular drugs. *Indian J Med Res* ; 89: 306-9.
- **Shafer RW, Kim DS, Weiss JP and et al.(1991).** Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. *Medicine.* ;70:384-397.

- **Shah S, Thomas V, Mathan M and et al.(1992).** Colonoscopic study of 50 patients with colonic tuberculosis. *Gut.* ;33:347-351.
- **Shah S, Thomas V, Mathan M and et al. (1992)** Colonoscopic study of 50 patients with colonic tuberculosis. *Gut.*;33:347-351.
- **Sharma S, Sarin R, Khalid UK, Singla N, Sharma PP and Behera D(2008).** The DOTS strategy for treatment of paediatric pulmonary tuberculosis in South Delhi, India. *Int J Tuberc Lung Dis* ; 12: 74–80.
- **Sharma SK(2004).** Antituberculosis drugs and hepatotoxicity. *Infect Genet Evol* ; 4:167-70.
- **Sharma SK, Balamurugan A, Saha PK, Pandey RM and Mehra NK(2002).** Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. *Am J Respir Crit Care Med* ;166:916-9.
- **Singh D (2003):** Practical problems of the tuberculin test. London 2003:345.
- **Singh MM, Bhargava AN and Jain KP(1969).** Tuberculous peritonitis: an evaluation of pathogenetic mechanisms, diagnostic procedures and therapeutic measures. *N Engl J Med.* ;281:1091-1094
- **Slavin RE, Walsh TJ and Pollack AD(2000):** Late generalized tuberculosis: A clinical pathologic analysis and comparison of 100 cases in the preantibiotic and antibiotic eras. *Medicine* 59:352-358.
- **Slovis BS, Plitman JD and Haas DW(2007).** The case against anergy testing as a routine adjunct to tuberculin skin testing. *JAMA.* 2000;283:2003-2007.
- **Snider DE Jr(1982).** The tuberculin skin test. *Am Rev Respir Dis.* 1982;125:108-118.

- **Snider DE(2000).** Ethical issues in tuberculosis vaccine trials. *Clin Infect Dis* ; **30** (suppl 3): S271–75.
- **Society of Osteology Sachsen E. V. (2006).** Soeters M, de Vries AM, Kimpen JL, Donald PR and Schaaf HS(2005). Clinical features and outcome in children admitted to a TB hospital in the Western Cape—the influence of HIV infection and drug resistance. *S Afr Med J* ; 95: 602–06.
- **Sokal JE(1975).** Measurement of delayed skin-test responses. *N Engl J Med* 1975;293:501-2.
- **Soriano, V, Tor, J., Domenecn, E. and et al.(1991).** Abdominal tuberculosis in patients with acquired immunodeficiency syndrome. *Med. Clin. (Barcelona)*; 97.121.
- **Spiegel, C.T. and Tuczon, C.U(1984).** Tuberculosis liver abscess. *Tubercle*; 65,127.
- **Spyridis P, Sinaniotis C, Papadea I, Oreopoulos L, Hadjiyiannis S and Papadatos C(1979).** Isoniazid liver injury during chemoprophylaxis in children. *Arch Dis Child* ; 54: 65-67.
- **Starke ,Jeffrey and Taylor-Watt ,T .,Kym(1989).** Tuberculosis in the pediatric population in houston ped. 84,1,28-35.
- **Starke JR (2001):** Transmission of Mycobacterium tuberculosis to and from children and adolescents. *Semin Pediatr Infects Dis*; 12: 115- 23.
- **Starke JR (2003):** Pediatric tuberculosis: time for a new approach. *Tuberculosis*2003;83:208-12.
- **Starke JR(2000).** Diagnosis of tuberculosis in children. *Pediatr Infect Dis J* 2000; 19: 1095–96.
- **Starke JR, Jacobs RF and Jereb J(1992).** Resurgence of tuberculosis in children. *J Pediatr* ; 120: 839-855.

- **Starke, J(2006).** Use of the new TB test in children should be limited. *AAP News* ; 27:14.
- **Starke, JR(2000).** Tuberculosis in childhood and pregnancy: In: Friedman LN, editor. *Tuberculosis: current concepts and treatment*. 2nd ed. Boca Raton: CRC Press; .
- **Starke, JR(2003).** Pediatric tuberculosis: time for a new approach. *Tuberculosis (Edinb)* ; 83:208.
- **Starke, JR(2007).** New concepts in childhood tuberculosis. *Curr Opin Pediatr* ; 19:306.
- **Stead WW(1995).** Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. *Ann Intern Med.* ;122:906-912.
- **Steele MA, Burk RF and DesPrez RM(1991).** Toxic hepatitis with isoniazid and rifampin: a metaanalysis. *Chest* ; 99: 465–471.
- **Sterne JA, Rodrigues LC and Guedes IN(1998).** Does the efficacy of BCG decline with time since vaccination? *Int J Tuberc Lung Dis* ;2: 200–07.
- **Strake JR and Munoz FM (2008):** Tuberculosis in: Behrman RE, Kliegman RM and Jenson HB. Editors. *Nelson Textbook of Pediatrics*. 18th ed. Saunders Company, Philadelphia; P:1240.
- **Strang JI, Kakaza HH, Gibson DG and et al.(1987).** Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. *Lancet* ; 2: 1418–1422.
- **Strang JI, Nunn AJ, Johnson DA and et al.(2004).** Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. *QJM* ; 97: 525–535.
- **Styblo K(1980).** Recent advances in epidemiological research in tuberculosis. *Adv Tuberc Res.* ;20:1-63.

- **Sundaram, G., McDonald, R.J., Maniatis, T. and et al.(1986).** Tuberculosis as a manifestation of the acquired immunodeficiency syndrome. *J.A.M.A.*; 256, 362.
- **Tahaoğlu K, Ataç G, Sevim T, Tärün T, Yazicioğlu O, Horzum G and et al.(2001).** The management of anti-tuberculosis drug-induced hepatotoxicity. *Int J Tuberc Lung Dis* ; 5: 65-9.
- **Takeda E, Yamamoto H, Taketani Y and Miyamoto K (2000):** Vitamin D-dependant rickets type I and type II. *Acta Pediatr Jpn.* Aug :508-13.
- **Takeyama K, Kitanka S, Sato T and et al. (2004):** 25 hydroxy vitamin D3-1 alpha hydroxylase and vitamin D synthesis . *Science*, 277:1827.
- **Talat N and Pal P (2004):** Vitamin D deficiency and pulmonary tuberculosis in eastern province of Pakistan. *Annals of Tropical Paediatric: International Child Health*, 27, 63-67.
- **Teklu,B.&Al-Wabel,A.H.(1994):**Resolution of fever in patient on chemotherapy for pulmonary T.B. *Ann.saudi.Med.*1994;14/5(392-395). the classical pathway in human bronchoalveolar lavage fluid. *Infect Immun.* ;72: 2564-2573.
- **Terry R.B. and Gunnar R.M(1957).** Primary miliary tuberculosis of the liver, *J.A.M.A.*; 164, 150.
- **The National Collaborating Centre for Chronic Conditions(2006).** Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control. London, Royal College of Physicians.
- **Thwaites GE, Nguyen DB, Nguyen HD and et al(2004).** Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. *N Engl J Med* ; 351:1741.

- **Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ and Dekhuijzen R.(2008):** Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. *J Gastroenterol Hepatol.* 2008 Feb;23(2):192-202. Epub 2007 Nov 6.
- **Trunz BB, Fine PE and Dye C(2006).** Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: ameta-analysis and assessment of cost-eff ectiveness. *Lancet* ;367: 1173–80.
- **Tsagaropoulou-Stinga H, Matakis-Emmanouilidou T, Karida-Kavalioti S and Manios S(1985).** Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. *Pediatr Infect Dis* ; 4:270-3.
- **Tsakalidis D, Pratsidou P, Hitoglou-Makedou A, Tzouvelekis G and Sofroniadis I(1992).** Intensive short course chemotherapy for treatment of Greek children with tuberculosis. *Pediatr Infect Dis J* ; 11: 1036-42.
- **Valway SE, Sanchez MPC, Shinnick TK and et al.(1998).** An outbreak involving extensive transmission of a virulent strain of *Mycobacterium tuberculosis*. *N Engl J Med.* ;338:633-639.
- **Van Crevel R, Ottenhoff THM and van der Meer JWM(2002).** Innate immunity to *Mycobacterium tuberculosis*. *Clin Microbiol Rev.* ;15:294-309.
- **Veith R (2004):** Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. *Am J Clin Nutr.* May; 69(5):842-56.
- **Visudhiphan P and Chiemchanya S(1989).** Tuberculous meningitis in children: treatment with isoniazid and rifampicin for twelve months. *J Pediatr* ; 114: 875-9.
- **Walls T and Shingadia D (2004):** Global epidemiology of pediatric tuberculosis. *J Infect.* 2004; 48:13-22.

- **Weinberg, J.J., Cohen, P. and Malhotra, R(1988).** Primary tuberculous abscess associated with the human immunodeficiency virus. *Tubercle*; 69, 145
- **Wejse C, Gomes VF, Rabna P and et al.(2009).** Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebocontrolled trial. *Am J Respir Crit Care Med* ; 179: 843–850.
- **Wells CD, Cegielski JP, Nelson LJ and et al.(2007).** HIV infection and multidrug-resistant tuberculosis: the perfect storm. *J Infect Dis* ; 196 (suppl 1): S86–107.
- **Whalen CC, Johnson JL, Okwera A and et al.(1997).** A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. *N Engl J Med.*;337:801-808.
- **Wharton B and Bishop N (2003):** Rickets. *Lancet*; 362: 1389-1400.
- **WHO(2006).** Considerations for infants and children coinfectd with tuberculosis and HIV. In: *Antiretroviral therapy of HIV in infants and children: towards universal access*. Geneva: World HealthOrganization, : 43–48.
- **WHO(2006).** Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva: World Health Organization,2006.http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf (accessed June 19, 2008).
- **WHO(2006).** Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva: World Health Organization. http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf (accessed June 19, 2008).

- **WHO(2006).** The global plan to stop TB, 2006–2015. Annex 1. Methods used to estimate costs, funding and funding gaps. Geneva: WorldHealth Organization,
http://whqlibdoc.who.int/publications/2006/924159487X_eng.pdf
(accessed June 19, 2008).
- **Wilkinson RJ, Llewelyn M, Toossi Z and et al.(2000).** Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. *Lancet* ; 355: 618–621.
- **Willheim M, Thein R, Schratlbauer K and et al. (2003):** Regulatory effects of 1,25(OH)₂D₃ on the cytokine production of human peripheral blood lymphocytes. *J. Clin. End. Met* 84 (10): 3739-44.
- **Williams, Amanda J. MRCPCH; Anderson and Suzanne T(2008):** *Pediatric Infectious Disease Journal* Oct. 2008 - Volume 27 - Issue 10 - pp 941-942.
- **Windaus, A, Schenck, F and Von Werder, F(1936).** About the antirachitic irradiation product of 7-dehydrocholesterol. *Hoppe Seylers Z Physiol Chem* ; 241:100.
- **World Health Organization (2006).**Guidance for national tuberculosis programmes on the management of tuberculosis in children.. WHO/HTM/ TB/2006.371.
- **World health organization (2009).**Treatment of TB guidelines:4th edn.WHO/HTM/TB/2009.420.
- **World Health Organization(1997) Report on the Tuberculosis Epidemic.** Geneva: World Health Organization.
- **World Health Organization(2006),** Childhood TB Subgroup. Guidance for national tuberculosis programmes on the

- management of tuberculosis in children, Geneva. WHO/HTM/TB/2006.371WHO/FCH/CAH/.7.
- **World Health Organization(2008).** Global Tuberculosis Database. Available at <<http://www.who.int/research/en/>>; Accessed November 2008.
 - **World Health Organization(2010).** Global Tuberculosis Control 2010. WHO/HTM/TB/2010.7. Geneva, World Health Organization,2010.
 - **Wu SS, Chao CS, Vargas JH, Sharp HL, Martín MG, McDiarmid SV, Sinatra FR and Ament ME(2007).** Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. *Transplantation* ; 84:173-9.
 - **Yamshchikov AV and et al. (2010).** Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. *Am. J. Clin. Nutr.* 92:603–611.
 - **Zaleskis R(2005).** The side-effects of TB therapy. *Breathe* ; 2: 69-73.
 - **Zar HJ, Cotton MF, Strauss S and et al.(2007).** Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. *BMJ* ; 334: 136.
 - **Zar, HJ, Hanslo, D, Apolles, P and et al.(2005).** Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. *Lancet* ; 365:130.
 - **Zhu M, Starke JR, Burman WJ and et al.(2002).** Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. *Pharmacotherapy* ; 22: 686–95.

- **Zuber PLF, McKenna MT, Binkin NJ and et al.(1997).**Long-term riskof tuberculosis among foreign-born persons in the United States.*JAMA*.;278:304-307.